Translational research in acute kidney injury, sepsis and critical illness.
Research in the lab is aimed at identifying novel approaches to prevent AKI and treat patients with sepsis and critical illness. Our research is highly collaborative and includes: randomized control trials, biomarker studies to improve phenotyping of patients with sepsis-associated AKI, genetics and molecular epidemiology studies.
- Discovering novel approaches to molecular phenotype AKI and advancing precision medicine for AKI.
- Investigating therapeutics and novel treatment strategies to improve outcomes in patients with AKI, COVID-19, and sepsis in the ICU.
- Developing methods to improve the diagnosis and prognosis of patients with cystic fibrosis who are at risk of AKI.
For more on our work, see our publications.
Pavan Bhatraju, MD MSc, discusses the lab’s work in molecular phenotyping acute kidney injury and its implications for precision medicine.
We are a team of scientists, clinicians and collaborators seeking to better understand AKI and care for patients with critical illness. Join us!